# Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int

> **NCT03213964** · PHASE1 · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 10 (actual)

## Conditions studied

- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer

## Interventions

- **BIOLOGICAL:** FATE-NK100
- **DRUG:** Interleukin-2

## Key facts

- **NCT ID:** NCT03213964
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-19
- **Primary completion:** 2021-03-10
- **Final completion:** 2021-03-10
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2021-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03213964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03213964, "Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03213964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*